Grants and Contributions:
Title:
Commercialization Strategy for Marketing Finished Product
Agreement Number:
1031097
Agreement Value:
$24,900.00
Agreement Date:
Jun 1, 2025 - Nov 3, 2025
Description:
The project will prepare a portfolio for commercialization of the product to launch to market.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T6R 0L1
Reference Number:
172-2025-2026-Q1-1031097
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
782772487
Recipient Type:
For-profit organization
Recipient's Operating Name:
RS Therapeutics Inc.
Recipient's Legal Name:
RS Therapeutics Inc.
Federal Riding Name:
Edmonton Riverbend
Federal Riding Number:
48018
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
32541